Why taking the trip out of psychedelic medicine is a mistake.
Julian Heller, Yogi Hale Hendlin
International Journal of Drug Policy September 9, 2026 DOI: 10.1016/j.drugpo.2026.105487 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Keywords | Ecodelics Pharmaceuticalization Psychedelics Psychoplastogens Subjective experience |
| Key points | Argues that the pharmaceutical turn toward 'psychoplastogens'—psychedelics engineered to exclude subjective experience—misconstrues subjective experience as pathological noise rather than the principal mechanism of action, and risks eliminating the relational, ecological, and transformative benefits of psychedelics, which the authors contend are non-specific amplifiers dependent on set, setting, and social context. |
Abstract
A 2022 article in Nature proclaimed the possibility of "Taking the tripping out of psychedelic medicine," highlighting efforts to engineer medically-compliant designer psychedelics purportedly delivering mental health benefits without inducing subjective experiences. Such developments have since initiated a new mainstream in the pharmaceuticalization and commodification of psychedelics. These so-called 'psychoplastogens' streamline drugs to maximize scalability, standardization, and compatibility with medical and economic infrastructures. Yet stripping psychedelics of their phenomenological core, risks eliminating their most transformative therapeutic and societal effects. Drawing on 'ecodelics,' i.e., psychedelics understood as agents of relational and ecological attunement, we assess biochemical reductionist framings of psychedelic medicine, foregrounding the crucial role of set, setting, and social context (matrix). The pharmaceuticalization of psychedelics risks narrowing these substances to individualized biochemical interventions, sidelining the relational, ecological, and transformative dimensions through which they exert their broader therapeutic and societal benefits. Psychedelics' capacity to foster connectedness - to self, community, and nature - cannot be engineered out without consequence. We argue that the pharmaceutical turn in psychedelic science, while motivated by scalability and safety (and profit), indicates a deeper category error: treating subjective experience as pathological noise rather than as the principal mechanism of action. We argue for reintegrating psychedelics into relational, communal, and ecologically attuned practices, recognizing psychedelics not merely as isolated pharmacological agents but as non-specific amplifiers of experience dependent on social and ecological reinforcing scaffolding. If psychedelics are co-opted to sustain unsustainable systems, their emancipatory potential risks being lost at a moment when it is most urgently needed.
Citations in the library
Cites 43
- REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics Pharmacological Reviews June 20, 2019
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology December 1, 2011
- Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression Journal of Humanistic Psychology June 19, 2017
- The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects. ACS Pharmacology & Translational Science December 10, 2020
- Constructing drug effects: A history of set and setting Drug Science, Policy and Law 2017
and 38 more in the library